InvestorWire NewsRoom


Predictive Oncology’s (NASDAQ: POAI) Subsidiary Refining, Strengthening Personalized Oncology Approach to Ovarian Cancer
April 19, 2021

Predictive Oncology’s (NASDAQ: POAI) Subsidiary Refining, Strengthening Personalized Oncology Approach to Ovarian Cancer

  • Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of female reproductive system
  • TumorGenesis can provide pharmaceutical companies newfound ability for more effective, expeditious drug development
  • Company is global developer of world-class, innovative technologies using 3D cell culture, media

In the treatment of cancer, most patients receive standard one-size-fits-all drug treatments identified from studying the cancers, treatments and results of other patients. In the evolving world of personalized oncology, the approach entails testing a variety of potential drugs on a patient’s unique tumor to discover which drug, or combination of drugs, might work best. That is precisely the approach that Predictive Oncology (NASDAQ: POAI), through its subsidiary TumorGenesis, takes in addressing ovarian cancer.

According to the American Cancer Society, ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system ( The ACS estimated that in 2021, more than 21,000 women will be diagnosed with ovarian cancer, with more than 13,000 women dying from it.

The standard of care for ovarian cancer patients is the use of cisplatin, or carboplatin, in combination with taxol in alternating treatments following surgery weekly with intraperitoneal and intravenous infusions of the two different drugs, one IV and the other IP, then alternating; only 40–50% of patients survive past five years ( TumorGenesis, through its proprietary TumorGenesis tumor modeling, is confident it can provide pharmaceutical companies newfound ability for more effective and expeditious drug development and, as a result, improve patient outcomes.

That’s a lofty claim, but one that TumorGenesis can back up with its innovative personalized oncology approach. The company is a global developer of world-class and innovative technologies using 3D cell culture and media; the company specializes in technology that preserves a patient’s unique cancer tissue biological signatures, thereby allowing researchers to study cancer in the laboratory using cancer samples that reflect the actual tumors found in a patient.

This idea of personalized oncology isn’t unique to TumorGenesis; however, personalized oncology has been generally unsuccessful in the past because cell lines can only be established from less than 1% of all ovarian cancers. TumorGenesis technology enables cell lines from patients to represent more than 90% of patient tumors that the current 1% of ovarian cancer cells available for research don’t represent — numbers that are transformative for ovarian cancer patient treatments.

The result, simply stated, assists health providers in selecting the most effective drug to treat a specific patient’s unique cancer — personalized medicine at its finest.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of more than 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.  

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).